tbuckley/cabot-search huggingface dataset:
Association Between Primary Care Practice Telehealth Use and Acute Care Visits for Ambulatory Care–Sensitive Conditions During COVID-19
Authors: Kathleen Y. Li, Sophia Ng, Ziwei Zhu, Jeffrey S. McCullough, Keith E. Kocher, Chad Ellimoottil
Journal: JAMA Network Open (2022)

<h3>Importance</h3> During the COVID-19 pandemic, many primary care practices adopted telehealth in place of in-person care to preserve access to care for patients with acute and chronic conditions. The extent to which this change was associated with their rates of acute care visits (ie, emergency department visits and hospitalizations) for these conditions is unknown. <h3>Objective</h3> To examine whether a primary care practice's level of telehealth use is associated with a change in their rate of acute care visits for ambulatory care–sensitive conditions (ACSC visits). <h3>Design, Setting, and Participants</h3> This retrospective cohort analysis used a difference-in-differences study design to analyze insurance claims data from 4038 Michigan primary care practices from January 1, 2019, to September 30, 2020. <h3>Exposures</h3> Low, medium, or high tertile of practice-level telehealth use based on the rate of telehealth visits from March 1 to August 31, 2020, compared with prepandemic visit volumes. <h3>Main Outcomes and Measures</h3> Risk-adjusted ACSC visit rates before (June to September 2019) and after (June to September 2020) the start of the COVID-19 pandemic, reported as an annualized average marginal effect. The study examined overall, acute, and chronic ACSC visits separately and controlled for practice size, in-person visit volume, zip code–level attributes, and patient characteristics. <h3>Results</h3> A total of nearly 1.5 million beneficiaries (53% female; mean [SD] age, 40 [22] years) were attributed to 4038 primary care practices. Compared with 2019 visit volumes, median telehealth use was 0.4% for the low telehealth tertile, 14.7% for the medium telehealth tertile, and 39.0% for the high telehealth tertile. The number of ACSC visits decreased in all tertiles, with adjusted rates changing from 24.3 to 14.9 per 1000 patients per year (low), 23.9 to 15.3 per 1000 patients per year (medium), and 27.5 to 20.2 per 1000 patients per year (high). In difference-in-differences analysis, high telehealth use was associated with a higher ACSC visit rate (2.10 more visits per 1000 patients per year; 95% CI, 0.22-3.97) compared with low telehealth practices; practices in the middle tertile did not differ significantly from the low tertile. No difference was found in ACSC visits across tertiles when acute and chronic ACSC visits were examined separately. <h3>Conclusions and Relevance</h3> In this cohort study that used a difference-in-differences analysis, the association between practice-level telehealth use and ACSC visits was mixed. High telehealth use was associated with a slightly higher overall ACSC visit rate than low telehealth practices. The association of telehealth with downstream care use should be closely monitored going forward.
EXTREMELY LARGE AORTIC ANNULUS TAVR USING OVER-EXPANDED EDWARDS SAPIEN 3 VALVE WITH RENAL FUNCTION AND FUNCTIONAL CLASS IMPROVEMENT AFTER THE PROCEDURE.
Authors: Enrique Alessio Garibo Luna, Jose Ramon Benitez, Andres Palacios Castañeda, Antonio Juarez
Journal: Journal of the American College of Cardiology (2022)
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting
Authors: Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL
Authors: Yuekun Qi, Mingfeng Zhao, Yongxian Hu, Ying Wang, Ping Li, Jiang Cao, Ming Shi, Jiaqi Tan, Meng Zhang, Xia Xiao, Jieyun Xia, Sha Ma, Jianlin Qiao, Zhiling Yan, Hujun Li, Bin Pan, Wei Sang, Depeng Li, Zhenyu Li, Jianfeng Zhou, He Huang, Aibin Liang, Junnian Zheng, Kailin Xu
Journal: Blood (2022)

Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system leukemia (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 patients with relapsed/refractory B-ALL with CNSL to evaluate the efficacy and safety of CD19-specific CAR T cell–based therapy. The infusion resulted in an overall response rate of 87.5% (95% confidence interval [CI], 75.3-94.1) in bone marrow (BM) disease and remission rate of 85.4% (95% CI, 72.8-92.8) in CNSL. With a median follow-up of 11.5 months (range, 1.3-33.3), the median event-free survival was 8.7 months (95% CI, 3.7-18.8), and the median overall survival was 16.0 months (95% CI, 13.5-20.1). The cumulative incidences of relapse in BM and CNS diseases were 31.1% and 11.3%, respectively, at 12 months (P = .040). The treatment was generally well tolerated, with 9 patients (18.8%) experiencing grade ≥3 cytokine release syndrome. Grade 3 to 4 neurotoxic events, which developed in 11 patients (22.9%), were associated with a higher preinfusion disease burden in CNS and were effectively controlled under intensive management. Our results suggest that CD19-specific CAR T cell–based therapy can induce similar high response rates in both BM and CNS diseases. The duration of remission in CNSL was longer than that in BM disease. CD19 CAR T-cell therapy may provide a potential treatment option for previously excluded patients with CNSL, with manageable neurotoxicity. The clinical trials were registered at www.clinicaltrials.gov as #NCT02782351 and www.chictr.org.cn as #ChiCTR-OPN-16008526. Subjects: Clinical Trials and Observations, Free Research Articles, Immunobiology and Immunotherapy, Lymphoid Neoplasia
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Authors: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, Jens Bedke, Umberto Capitanio, Saeed Dabestani, Sergio Fernández-Pello, Rachel H. Giles, Fabian Hofmann, Milan Hora, Tobias Klatte, Teele Kuusk, Thomas B. Lam, Lorenzo Marconi, Thomas Powles, Rana Tahbaz, Alessandro Volpe, Axel Bex
Journal: European Urology (2022)

The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines. All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence. The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022. The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.
LONG-TERM OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH END STAGE LIVER DISEASE
Authors: Kris Kumar, Craig C. Morris, Ashraf Samhan, Tessa Herman, Trisha Chau, Gurion Lantz, Scott M. Chadderdon, Howard K. Song, Firas E. Zahr, Harsh Golwala
Journal: Journal of the American College of Cardiology (2022)
SSPNet: An interpretable 3D-CNN for classification of schizophrenia using phase maps of resting-state complex-valued fMRI data
Authors: Qiu-Hua Lin, Yan-Wei Niu, Jing Sui, Wen-Da Zhao, Chuanjun Zhuo, Vince D. Calhoun
Journal: Medical Image Analysis (2022)

Convolutional neural networks (CNNs) have shown promising results in classifying individuals with mental disorders such as schizophrenia using resting-state fMRI data. However, complex-valued fMRI data is rarely used since additional phase data introduces high-level noise though it is potentially useful information for the context of classification. As such, we propose to use spatial source phase (SSP) maps derived from complex-valued fMRI data as the CNN input. The SSP maps are not only less noisy, but also more sensitive to spatial activation changes caused by mental disorders than magnitude maps. We build a 3D-CNN framework with two convolutional layers (named SSPNet) to fully explore the 3D structure and voxel-level relationships from the SSP maps. Two interpretability modules, consisting of saliency map generation and gradient-weighted class activation mapping (Grad-CAM), are incorporated into the well-trained SSPNet to provide additional information helpful for understanding the output. Experimental results from classifying schizophrenia patients (SZs) and healthy controls (HCs) show that the proposed SSPNet significantly improved accuracy and AUC compared to CNN using magnitude maps extracted from either magnitude-only (by 23.4 and 23.6% for DMN) or complex-valued fMRI data (by 10.6 and 5.8% for DMN). SSPNet captured more prominent HC-SZ differences in saliency maps, and Grad-CAM localized all contributing brain regions with opposite strengths for HCs and SZs within SSP maps. These results indicate the potential of SSPNet as a sensitive tool that may be useful for the development of brain-based biomarkers of mental disorders.
Associations between the Maternal Exposome and Metabolome during Pregnancy
Authors: Minjian Chen, Yusheng Guan, Rui Huang, Jiawei Duan, Jingjing Zhou, Ting Chen, Xinru Wang, Yankai Xia, Stephanie J. London
Journal: Environmental Health Perspectives (2022)

Background: Maternal exposure to environmental chemicals during pregnancy can influence various maternal and offspring health parameters. Modification of maternal metabolism by environmental exposure may be an important pathway for these impacts. However, there is limited evidence regarding exposure to a wide array of chemicals and the metabolome during pregnancy. Objectives: We investigated the relationship between the urinary exposome and metabolome during pregnancy. Methods: Urine samples were collected in the first and third trimesters from 1,024 pregnant women recruited in prenatal clinics in Jiangsu Province, China. The exposome was analyzed using the first trimester sample with ultra-high performance liquid chromatography–high resolution accurate mass spectrometry (UHPLC-HRMS) and inductively coupled plasma mass spectrometry. The metabolome was analyzed using the third trimester sample with UHPLC-HRMS. We evaluated associations between each of 106 exposures in the first trimester with 139 metabolites in the third trimester. Results: We identified 1,245 significant associations (p&lt;3.39×10−6, Bonferroni correction) between chemical exposures and maternal metabolism during pregnancy. Among elements, the largest number of the significant metabolic associations were observed for magnesium, and among organic compounds, for 4-tert-octylphenol. We used exposome–metabolome associations to explore mechanisms underlying published associations between prenatal chemical exposures and offspring health outcomes. This integration of the literature with our results suggests that reported associations between 10 analytes and birth weight, gestational age, fat deposition, neurobehavioral development, immunological disorders, and hypertension may be partially mediated by metabolites associated with these exposures. Discussion: This high-dimensional analysis of the urinary exposome and metabolome identified many associations between chemical exposures and maternal metabolism during pregnancy. Integration of these associations with the literature on health outcomes of exposure suggests that environmental modulation of the maternal metabolome may play a role in the association between prenatal exposure on pregnancy and child health outcomes. https://doi.org/10.1289/EHP9745
Airborne transmission: Are CO<sub>2</sub>monitors a long term solution or “pandemic hack?”
Authors: Chris Baraniuk
Journal: BMJ (2022)

As more people have acknowledged the airborne transmission of SARS-CoV-2, CO<sub>2</sub> monitors have emerged as a cost effective way to tell how well ventilated a space is. <b>Chris Baraniuk</b> asks what the evidence is and if they should be adopted more widely
“MATERNAL HEART” - AN UNCOMMON CASE OF PERIPARTUM CARDIOMYOPATHY PRESENTING WITH PULMONARY EMBOLISM
Authors: Arnaldo Nieves Ortiz, Debora Zamora-Olivencia, Vanessa Fonseca-Ferrer, Stephanie Gonzalez-Garcia, Yesenia Fuentes-Perez, Nilmar Nieves-Ortiz, Kyomara Hernandez-Moya, David Aguirre-Guzman, Teodosio Rucabado-Bruno
Journal: Journal of the American College of Cardiology (2022)
Observing effects in various contexts won't give us general psychological theories
Authors: Chris Donkin, Aba Szollosi, Neil R. Bramley
Journal: Behavioral and Brain Sciences (2022)

Generalization does not come from repeatedly observing phenomena in numerous settings, but from theories explaining what is general in those phenomena. Expecting future behavior to look like past observations is especially problematic in psychology, where behaviors change when people's knowledge changes. Psychology should thus focus on theories of people's capacity to create and apply new representations of their environments.
Cannabis Legalization and Detection of Tetrahydrocannabinol in Injured Drivers
Authors: Jeffrey R. Brubacher, Herbert Chan, Shannon Erdelyi, John A. Staples, Mark Asbridge, Robert E. Mann
Journal: New England Journal of Medicine (2022)

The effect of cannabis legalization in Canada (in October 2018) on the prevalence of injured drivers testing positive for tetrahydrocannabinol (THC) is unclear.We studied drivers treated after a motor vehicle collision in four British Columbia trauma centers, with data from January 2013 through March 2020. We included moderately injured drivers (those whose condition warranted blood tests as part of clinical assessment) for whom excess blood remained after clinical testing was complete. Blood was analyzed at the provincial toxicology center. The primary outcomes were a THC level greater than 0, a THC level of at least 2 ng per milliliter (Canadian legal limit), and a THC level of at least 5 ng per milliliter. The secondary outcomes were a THC level of at least 2.5 ng per milliliter plus a blood alcohol level of at least 0.05%; a blood alcohol level greater than 0; and a blood alcohol level of at least 0.08%. We calculated the prevalence of all outcomes before and after legalization. We obtained adjusted prevalence ratios using log-binomial regression to model the association between substance prevalence and legalization after adjustment for relevant covariates.During the study period, 4339 drivers (3550 before legalization and 789 after legalization) met the inclusion criteria. Before legalization, a THC level greater than 0 was detected in 9.2% of drivers, a THC level of at least 2 ng per milliliter in 3.8%, and a THC level of at least 5 ng per milliliter in 1.1%. After legalization, the values were 17.9%, 8.6%, and 3.5%, respectively. After legalization, there was an increased prevalence of drivers with a THC level greater than 0 (adjusted prevalence ratio, 1.33; 95% confidence interval [CI], 1.05 to 1.68), a THC level of at least 2 ng per milliliter (adjusted prevalence ratio, 2.29; 95% CI, 1.52 to 3.45), and a THC level of at least 5 ng per milliliter (adjusted prevalence ratio, 2.05; 95% CI, 1.00 to 4.18). The largest increases in a THC level of at least 2 ng per milliliter were among drivers 50 years of age or older (adjusted prevalence ratio, 5.18; 95% CI, 2.49 to 10.78) and among male drivers (adjusted prevalence ratio, 2.44; 95% CI, 1.60 to 3.74). There were no significant changes in the prevalence of drivers testing positive for alcohol.After cannabis legalization, the prevalence of moderately injured drivers with a THC level of at least 2 ng per milliliter in participating British Columbia trauma centers more than doubled. The increase was largest among older drivers and male drivers. (Funded by the Canadian Institutes of Health Research.).
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Authors: Shoshana T. Levi, Amy R. Copeland, Shirley Nah, Jessica S. Crystal, Gabriel D. Ivey, Almin Lalani, Mohammad Jafferji, Bradley S. White, Neilesh B. Parikh, Vid Leko, Sri Krishna, Frank Lowery, Todd D. Prickett, Jared J. Gartner, Li Jia, Yong F. Li, Abraham Sachs, Sivasish Sindiri, Welles Robinson, Billel Gasmi, James C. Yang, Stephanie L. Goff, Steven A. Rosenberg, Paul F. Robbins
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation of lymphocytes that target shared tumor antigens or neoantigens. Recent analysis of patients with metastatic melanoma who underwent treatment with TIL ACT at the NCI demonstrated decreased responses in patients previously treated with anti–PD-1 agents. We aimed to find a basis for the difference in response rates between anti–PD-1 naïve and experienced patients. Patients and Methods: We examined the tumor mutational burden (TMB) of resected tumors and the repertoire of neoantigens targeted by autologous TIL in a cohort of 112 anti–PD-1 naïve and 69 anti–PD-1 experienced patients. Results: Anti–PD-1 naïve patients were found to possess tumors with higher TMBs (352.0 vs. 213.5, P = 0.005) and received TIL reactive with more neoantigens (2 vs. 1, P = 0.003) compared with anti–PD-1 experienced patients. Among patients treated with TIL ACT, TMB and number of neoantigens identified were higher in ACT responders than ACT nonresponders in both anti–PD-1 naïve and experienced patients. Among patients with comparable TMBs and predicted neoantigen loads, treatment products administered to anti–PD-1 naïve patients were more likely to contain T cells reactive against neoantigens than treatment products for anti–PD-1 experienced patients (2.5 vs. 1, P = 0.02). Conclusions: These results indicate that decreases in TMB and targeted neoantigens partially account for the difference in response to ACT and that additional factors likely influence responses in these patients. See related commentary by Blass and Ott, p. 2980
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?
Authors: Jose G. Bazan, Julia R. White
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PER-VESSEL AND PER-PATIENT DIAGNOSTIC PERFORMANCE OF COMMERCIAL CT-FFR ACCORDING TO PER-PATIENT AND PER-VESSEL CAC IN A HIGH CAC COHORT
Authors: Emem Udoh, Mohammad Aziz, Rajbir Sidhu, Ricardo Kosturakis, Melody Hermel, Carly Waldman, Samantha R. Spierling Bagsic, Shawn Newlander, Roy Avalos, Kamyar Haghani, Bahram Khadivi, Jason Parker Brown, Martin L. Charlat, Jeffrey J. Cavendish, Michael Salerno, Curtiss Stinis, Richard A. Schatz, Matthew J. Price, Paul S. Teirstein, Austin Robinson, Jorge A. Gonzalez, Sanjeev P. Bhavnani, George E. Wesbey
Journal: Journal of the American College of Cardiology (2022)
Improving Cohort Definitions in Research Using Hospital Administrative Databases—Do We Need Guidelines?
Authors: Matt Hall, Thomas M. Attard, Jay G. Berry
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH)
Authors: Deepak Kumar, Christina A. Rostad, Preeti Jaggi, D. Sofia Villacis Nunez, Chengyu Prince, Austin Lu, Laila Hussaini, Thinh H. Nguyen, Sakshi Malik, Lori A. Ponder, Sreekala P.V. Shenoy, Evan J. Anderson, Michael Briones, Ignacio Sanz, Sampath Prahalad, Shanmuganathan Chandrakasan
Journal: Journal of Allergy and Clinical Immunology (2022)
B lymphocyte-derived acetylcholine limits steady-state and emergency hematopoiesis
Authors: Maximilian J. Schloss, Maarten Hulsmans, David Rohde, I-Hsiu Lee, Nicolas Severe, Brody H. Foy, Fadi E. Pulous, Shuang Zhang, Konstantinos D. Kokkaliaris, Vanessa Frodermann, Gabriel Courties, Chongbo Yang, Yoshiko Iwamoto, Anders Steen Knudsen, Cameron S. McAlpine, Masahiro Yamazoe, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Gustavo Santos Masson, Karin Gustafsson, Diane Capen, Dennis Brown, John M. Higgins, David T. Scadden, Peter Libby, Filip K. Swirski, Kamila Naxerova, Matthias Nahrendorf
Journal: Nature Immunology (2022)